Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Fayi Wu; Stephanie O. Peacock; Shuyun Rao; Sandra Lemmon; Kerry L Burnstein

doi:10.1074/jbc.M112.390963

Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Fayi Wu, Stephanie O. Peacock, Shuyun Rao, Sandra Lemmon, Kerry L Burnstein

Molecular and Cellular Pharmacology

Research output: Contribution to journal › Article

17 Scopus citations

Abstract

Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

Original language	English
Pages (from-to)	5463-5474
Number of pages	12
Journal	Journal of Biological Chemistry
Volume	288
Issue number	8
DOIs	https://doi.org/10.1074/jbc.M112.390963
State	Published - Feb 22 2013

Fingerprint

ASJC Scopus subject areas

Biochemistry
Cell Biology
Molecular Biology

Cite this

Wu, F., Peacock, S. O., Rao, S., Lemmon, S., & Burnstein, K. L. (2013). Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth. Journal of Biological Chemistry, 288(8), 5463-5474. https://doi.org/10.1074/jbc.M112.390963

@article{f86d6cc5b36a444d99d27b9e60cb69a1,

title = "Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth",

abstract = "Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.",

author = "Fayi Wu and Peacock, {Stephanie O.} and Shuyun Rao and Sandra Lemmon and Burnstein, {Kerry L}",

year = "2013",

month = feb

day = "22",

doi = "10.1074/jbc.M112.390963",

language = "English",

volume = "288",

pages = "5463--5474",

journal = "Journal of Biological Chemistry",

issn = "0021-9258",

publisher = "American Society for Biochemistry and Molecular Biology Inc.",

number = "8",

}

TY - JOUR

T1 - Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

AU - Wu, Fayi

AU - Peacock, Stephanie O.

AU - Rao, Shuyun

AU - Lemmon, Sandra

AU - Burnstein, Kerry L

PY - 2013/2/22

Y1 - 2013/2/22

N2 - Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

AB - Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84874324273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874324273&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.390963

DO - 10.1074/jbc.M112.390963

M3 - Article

C2 - 23281476

AN - SCOPUS:84874324273

VL - 288

SP - 5463

EP - 5474

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 8

ER -

Access to Document

10.1074/jbc.M112.390963